Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 3, 2000, Pages 236-245

  Bonfanti, Paolo ^a   Valsecchi, Laura ^a   Parazzini, Fabio ^b   Carradori, Silvia ^c   Pusterla, Luigi ^d   Fortuna, Paolo ^e   Timillero, Lia ^f   Alessi, Federica ^g   Ghiselli, Giancarlo ^h   Gabbuti, Andrea ⁱ   Di Cintio, Elisabetta ^b   Martinelli, Canio ^j   Faggion, Ivano ^a   Landonio, Simona ^a   Quirino, Tiziana ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c S ANNA HOSPITAL   (Italy)

^d SANT ANNA HOSPITAL   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g CARLO POMA HOSPITAL   (Italy)

^h ASST Ovest Milanese   (Italy)

ⁱ S Anmmziata Hospital   (Italy)

^j CAREGGI UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

Adverse reactions; Antiretroviral therapy; Protease inhibitors; Surveillance

Indexed keywords

INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; ALLERGIC REACTION; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; SEXUAL DYSFUNCTION;

EID: 12944265462     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200003010-00004     Document Type: Article

References (36)

1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
3. Powderly WG, Landay A, Lederman M. Recovery of the immune system with antiretroviral therapy. The end of opportunism ? JAMA 1998;280:72-7.
4. Dubé MP, Johnson DL, Currier J, Leedom JM. Protease inhibitor-associated hyperglycemia. Lancet 1997;350:713-14.
5. Bonfanti P, Capetti A, Riva P, Testa L, Quirino T. Hypersensitivity reactions during antiretroviral regimens with protease inhibitors. AIDS 1997;11:1301-2.
6. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-9.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
8. D'Arminio Monforte A, Testa L, Gianotto M, et al. Indinavir-related alopecia. AIDS 1998;12:328.
9. Prazuck T, Semaille C, Roques S. Fatal acute haemolysis in AIDS patient treated with indinavir. AIDS 1998;12:531-3.
10. Chen SCA, Nankivell BJ, Dwyer DE. Indinavir-induced renal failure. AIDS 1998;12:440-1.
11. Martinez E, Collazos J, Mayo J, Blanco MS. Sexual dysfunction with protease inhibitors. Lancet 1999;353:810-11.
12. Nielsen H. Hypermenorrhea associated with ritonavir. Lancet 1999;353:811-12.
13. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factor for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
14. Mariani L, Minora T, Ventresca GP. Drug surveillance and adverse reactions to drugs. The literature and importance of historical data. Clin Ter 1996;147:653-72.
15. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
16. Bénichou C, Danan G. A new method for drug causality assessment: RUCAM. In: Bénichou C. Adverse drug reactions. a practical guide to diagnosis an management. New York: John Wiley & Sons, 1994:277-84.
17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Peto R, Pike MC, Armitage P. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Analysis and examples. Br J Cancer 1977;35:1-39.
19. Cox DR. Regression models and life tables. J Roy Stat Soc 1972; 34:187-220.
20. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71.
21. Saint-Marc T, Poizot Martin I, Partisani M. A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy [abstract 653]. VI Conference on Retroviruses arid Opportunistic Infections. Chicago, IL, U.S.A., 1999.
22. Karras A, Rabian C, Zylberger H, et al. Severe anoxic hepatic necrosis in an HIV-1-hepatitis virus co-infected patients starting antiretroviral triple combination therapy. AIDS 1998;12:827-829.
23. Zylberger H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998;27:1255-8.
24. Witt F, van Leeuween R, Weverling J, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type-1-infected persons. J Infect Dis 1999;179:790-8.
25. Casado J, Perez-Elias M, Antela A, et al. Risk factors for ritonavir intolerance and outcome after change to indinavir. AIDS 1998;12: 335-6.
26. Piroth L, Grappin M, Waldner A, et al. Discontinuation of protease inhibitors due to intolerance: a longitudinal study in 309 HIV-1 positive patients. Presse Med 1999;28:381-7.
27. Danner S, Carr A, Leonard J. A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. Clin Ther 1995;19:299-315.
28. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
29. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
30. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-17.
31. Meyer D, Behrens G, Schmidt RE, Stoll M. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999;13:1147-8.
32. Toma E, Therrien R. Gynecomastia during indinavir antiretroviral therapy in HIV infection. AIDS 1998;12:681-2.
33. Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics and antiretroviral activity of the potent, specific immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol 1998;38:736-43.
34. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatoxicity associated with antiretroviral therapy in adults infected with Human Immunodeficiency Virus and the role of hepatitis C or B Virus infection. JAMA 2000;283:74-80.
35. Rademaker J, Dobro JS, Solomon G. Osteonecrosis and human immunodeficiency virus infection J Rheumatol 1997;24:601-4.
36. Meyer D, Beherens G, Schmidt RE, Stoll M. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors. AIDS 1999;13:1147-8.